Boehringer Ingelheim International Gmbh

Novo Nordisk A/s

Neurosearch A/s

Boehringer Ingelheim Pharma Gmbh & Co Kg

Thomas Friedl

Joachim Mierau

Kenji Egusa

Wolfram Eisenreich

Takaaki Nishioka

Megumi Maruyama

Hikaru Fujita

Michael Braun

Nantharat Pearnchob

Florian Sommer

Karl Gerhard Wagner

Gottfried Schepky

Roman Messerschmid

Rolf-Stefan Brickl

Andreas Raschig

Roman Christian Messerschmid

Guido Bernhard Edmund Radtke

Manabu Nakatani

Koichi Wada

Jörgen Scheel-Krüger

Jürgen Reess

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.

Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Clower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.

Extended release tablet formulations of flibanserin and method for manufacturing the same

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.

Solid pharmaceutical formulations comprising BIBW 2992

The invention is directed to a pharmaceutical controlled release system for administration, particularly oral administration, of active substances with pH-dependent solubilities, comprising It is provided a pH-independent release profile of active substances having pH-dependent solubilities in vitro and vivo.

Controlled release system and method for manufacturing the same

An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.

Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Growing community of inventors

Ochsenhausen, Germany

Thomas Friedl